Enzon Inc. said Wednesday that it has received Food and DrugAdministration approval to conduct clinical trials of its Peg-L-asparaginase drug to qualify Kyowa Hakko Kogyo Ltd. as asupplier of L-asparaginase. The drug is awaiting FDA approvalto treat acute lymphoblastic leukemia. Earlier this month,Enzon of South Plainfield, N.J., (NASDAQ:ENZN) said it hadsigned a long-term supply agreement with Kyowa.
(c) 1997 American Health Consultants. All rights reserved.